Aspira Womens Health Inc SEC Filings

Aspira Women’s Health Inc. is registering 16,697,509 shares of common stock for resale by Lincoln Park Capital Fund, LLC under a committed equity financing arrangement. The registered shares include up to 15,873,016 shares that Aspira may sell to Lincoln Park over 24 months under a $10.0 million purchase agreement, plus 824,493 commitment shares already issued as a fee. Aspira will not receive proceeds from Lincoln Park’s resale of these shares, but can raise up to $10.0 million in gross proceeds from its own future sales of purchase shares to Lincoln Park, at prices tied to the market price of its stock. The company highlights potential dilution and stock price pressure from these issuances and resales, notes that its stock trades on the OTCQX under the symbol AWHL, and describes significant trading volatility and governance provisions that may affect control and liquidity.

Aspira Women’s Health Inc. is registering 16,697,509 shares of common stock for resale by Lincoln Park Capital Fund, LLC under a committed equity purchase arrangement.

The registered shares include up to 15,873,016 shares Aspira may sell to Lincoln Park over 24 months and 824,493 commitment shares already issued as a fee. Aspira will not receive proceeds from Lincoln Park’s resale of these shares, but may raise up to $10.0 million in gross proceeds from its own sales of purchase shares to Lincoln Park, with pricing based on future market prices.

Aspira had 43,480,411 common shares outstanding as of December 29, 2025, including the commitment shares, and estimates 59,353,427 shares would be outstanding if all purchase shares are issued. The stock trades on the OTCQX under the symbol AWHL, where it closed at $0.63 on December 29, 2025.

Aspira Women’s Health Inc. filed a current report to note that it has shared updated investor information with the market. On December 29, 2025, the company published an investor presentation on its website, providing a slide deck that outlines its business and related information for shareholders and other stakeholders. This slide deck is included as Exhibit 99.1 to the report. The filing is made under Regulation FD, which is intended to ensure that all investors have access to the same key information at the same time.

Aspira Women’s Health Inc. entered into a purchase agreement with Lincoln Park Capital Fund under which Lincoln Park committed to buy up to $10.0 million of Aspira’s common stock over up to 24 months, at Aspira’s discretion. Purchases will occur after a resale registration statement is declared effective and a final prospectus is filed.

On eligible days with a closing price above $0.10, Aspira may direct “Regular Purchases” of up to 50,000 shares, rising to 75,000 or 100,000 shares at higher price thresholds, each capped at $500,000. The purchase price is set at 95% of the lower of the sale price on the purchase date or the average of the three lowest closing prices over the prior ten business days, and may be supplemented by “Accelerated Purchases” based on trading volume.

Lincoln Park received commitment shares valued at 3.0% of the $10.0 million commitment, issued under private placement exemptions. The agreement limits Lincoln Park’s beneficial ownership to 4.99%, adjustable up to 9.99% with notice, includes no financial covenants, and generally restricts Aspira from entering other equity line arrangements during the 24‑month term.

Aspira Women’s Health entered into a Laboratory Services Agreement with Mayo Clinic Laboratories effective December 16, 2025. Aspira will perform its Ova1Plus (Ova1 and Overa) and OvaWatch ovarian cancer risk assessment tests for Mayo on a non-exclusive, as-requested basis for clinical use.

The initial term runs for five years with automatic one-year renewals, and either party may terminate for convenience with at least 90 days prior written notice or earlier for cause. Mayo will list the Aspira tests in its catalog, handle ordering, results delivery, and billing, while Aspira invoices Mayo at fixed fees during the initial term, subject to agreed adjustments. The agreement includes customary provisions on confidentiality, healthcare law compliance, insurance, indemnification, and non-exclusivity.

Aspira Women's Health Inc. director Cynthia Hundorfean reported receiving a stock option grant. On 12/02/2025, she was granted options to buy 238,085 shares of Aspira common stock at an exercise price of $0.35 per share. These options become exercisable on 12/02/2025 and expire on 12/02/2035. Following this grant, she beneficially owns 238,085 derivative securities directly.

Aspira Women's Health Inc.12/02/2025, the reporting person received a stock option, described as a right to buy up to 314,811 shares of the company’s common stock at an exercise price of $0.35 per share. The option becomes exercisable on the same date, 12/02/2025, and is scheduled to expire on 12/02/2035.

Following this grant, the reporting person beneficially owns 314,811 derivative securities directly in the form of this stock option. The form is signed by /s/ John D. Fraser, indicating his role as the reporting person and confirming the director status in relation to Aspira Women's Health.

Aspira Women's Health Inc. director reports new stock option grant. A director of Aspira Women's Health Inc. received a stock option on 12/02/2025 covering 135,592 shares of common stock. The option has an exercise price of $0.35 per share, is listed as exercisable on 12/02/2025, and expires on 12/02/2035. After this transaction, the director beneficially owns 135,592 derivative securities, held directly.

Aspira Women's Health Inc. reported an insider equity award for director Winfred Parnell. On 12/02/2025, Parnell received a stock option to buy 185,178 shares of common stock at an exercise price of $0.35 per share. The option becomes exercisable on 12/02/2025 and expires on 12/02/2035. After this award, Parnell beneficially owned 185,178 derivative securities directly.